Evommune, Inc. (NYSE:EVMN) — Market Cap & Net Worth
Market Cap & Net Worth: Evommune, Inc. (EVMN)
Evommune, Inc. (NYSE:EVMN) has a market capitalization of $769.35 Million ($769.35 Million) as of June 22, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #10242 globally and #2690 in its home market, demonstrating a 4.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evommune, Inc.'s stock price $21.36 by its total outstanding shares 36018372 (36.02 Million). Review debt load of Evommune, Inc. to assess the company's total debt and financial obligations.
Evommune, Inc. Market Cap History: 2025 to 2026
Evommune, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $616.63 Million to $769.35 Million (0.00% CAGR).
Evommune, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evommune, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
47.43x
Evommune, Inc.'s market cap is 47.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $616.63 Million | $13.00 Million | -$68.87 Million | 47.43x | N/A |
Competitor Companies of EVMN by Market Capitalization
Companies near Evommune, Inc. in the global market cap rankings as of June 22, 2026.
Key companies related to Evommune, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Evommune, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Evommune, Inc.'s market cap moved from $616.63 Million to $ 769.35 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $769.35 Million | +24.77% |
| 2025 | $616.63 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Evommune, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $769.35 Million USD |
| MoneyControl | $769.35 Million USD |
| MarketWatch | $769.35 Million USD |
| marketcap.company | $769.35 Million USD |
| Reuters | $769.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more